drugset / Trial / NCT07610564

A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

NCT07610564

Phase 1 Not yet recruiting 60 enrolled argenx
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects. The study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months. The total study duration for each participant will be approximately 29 months. More information can be found here: clinicaltrials.argenx.com/empasound

Timeline

Start
2026-06-30
Primary completion
2028-02-01
Completion
2030-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Empasiprubart Monoclonal antibody Intravenous